Payload Information
General Information of This Payload
| Payload ID | PAY0KXQHC |
|||||
|---|---|---|---|---|---|---|
| Name | PBX-7014 |
|||||
| Synonyms |
PBX-7014
Click to Show/Hide
|
|||||
| Target | DNA topoisomerase I (TOP1) | |||||
| Structure |
|
|||||
| Formula | C26H23N3O8 |
|||||
| Isosmiles | CC[C@]1(O)C(C=C2C3=NC4=C5C([C@@H](NC(CO)=O)CCC5=C(OCO6)C6=C4)=C3CN72)=C(COC1=O)C7=O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C26H23N3O8/c1-2-26(34)14-5-17-22-12(7-29(17)24(32)13(14)9-35-25(26)33)21-15(27-19(31)8-30)4-3-11-20(21)16(28-22)6-18-23(11)37-10-36-18/h5-6,15,30,34H,2-4,7-10H2,1H3,(H,27,31)/t15-,26-/m0/s1
|
|||||
| InChIKey |
LAFMRBJBBODCPL-HAWMADMCSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
505.483 |
Polar area |
149.21 |
||
Complexity |
1585.23321 |
xlogp Value |
0.9041 |
|||
Heavy Count |
37 |
Rot Bonds |
3 |
|||
Hbond acc |
10 |
Hbond Donor |
3 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Half maximal Inhibitory Concentration (IC50) | 1.557 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
[1] | |
| Half maximal Inhibitory Concentration (IC50) | 1.557 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
[1] | |
| Half maximal Inhibitory Concentration (IC50) | 2.607 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
[1] | |
| Half maximal Inhibitory Concentration (IC50) | 2.607 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
[1] | |
| Half maximal Inhibitory Concentration (IC50) | 4.539 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
[1] | |
| Half maximal Inhibitory Concentration (IC50) | 4.539 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
[1] |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Tra-25-4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.1192 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cell viability analysis of MDA-MB-453 (HER2+++) cell line, FaDu (HER2+) cell line and MDA-MB-468 (HER2-) cell line in vitro.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
34.5 nM
|
Low HER2 expression (HER2+) | ||
| Method Description |
Cell viability analysis of MDA-MB-453 (HER2+++) cell line, FaDu (HER2+) cell line and MDA-MB-468 (HER2-) cell line in vitro.
|
||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
128.8 nM
|
Negative HER2 expression (HER2-) | ||
| Method Description |
Cell viability analysis of MDA-MB-453 (HER2+++) cell line, FaDu (HER2+) cell line and MDA-MB-468 (HER2-) cell line in vitro.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
References